None identified

Hazard statements (CLP)

H227, H315, H340, H350

Code

Statements

H227

Combustible liquid

2.1 Classification of the substance or mixture

Globally Harmonized Flammable liquid - Category 4. Germ Cell Mutagenicity - Category 1B. Carcinogenic - System [GHS] Category 1B. Irritant (skin) - Category 2. AU Hazard Classification

Hazardous Ingredients

Non-hazardous goods (NOHSC)

Signal word

Danger

CLP CLASSIFICATION

H227 - Combustible liquid. H315 - Causes skin irritation. H340 - May cause genetic defects.

Hazard statements

H350 - May cause cancer. CLP/GHS precautionary P201 - Obtain special instructions before use. P210 - Keep away from heat/sparks/ open flames/hot surfaces. - No smoking. P264 - Wash hands thoroughly after handling. P280 - Wear protective gloves/eye protection/face protection. P302 + P352 - If on skin: Wash with plenty of soap and water. P321 - Specific treatment (see First Aid information on product label and/or Section 4 of the SDS). P308 + P313 - If exposed or concerned: get medical advice/attention. P332 + P313 - If skin irritation occurs: Get medical advice/attention. P362 - Take off contaminated clothing and wash before reuse. P370 +P378 - In case of fire: Use water spray (fog), foam, dry powder or carbon dioxide for extinction. P403 + P235 - Store in a well-ventilated place. Keep cool. P405 - Store locked up. P501 - Dispose of contents/container to location in accordance with local/regional/national/ international regulations.

2.3 Other hazards

Mixture contains cisplatin, a cytotoxic anticancer agent. The most common adverse effects reported in with clinical use of cisplatin include severe nausea and vomiting, peripheral neuropathies (pain or numbness in the extremities), kidney toxicity, myelosuppression (characterized by decreases in white blood cells and platelets), hearing loss, and ocular toxicity. Cumulative renal insufficiency is the major dose-limiting toxicity of cisplatin. Allergic reactions, including facial swelling, wheezing, fast heart rate, and hypotension, have also been reported and may occur within minutes of drug administration. Other reported adverse effects have included hair loss, malaise, cardiac abnormalities, rash, and asthenia (weakness). Cisplatin and other platinum-containing salts are considered to be to irritating and corrosive to skin after direct contact, capable of inducing a burning sensation in the eyes, lacrimation, and conjunctival hyperemia (increased blood flow into the eyeball), and irritating to the respiratory tract following inhalation. Cisplatin exposure has been associated with decreased spermatogenesis and abnormal Leydig cell function in men. Sperm production was found to return to normal in 50-60% of men between 1 and 3 years following treatment cessation. Based on its mechanism of action and the embryotoxicity noted in animals, cisplatin may adversely affect a developing fetus. Note This mixture is classified as hazardous according to Regulation EC No 1272/2008 (EU CLP) and Hazard Communication Standard No. 1910.1200 (US OSHA).